MetaStat, Inc. announced results from two clinical studies of its MetaSite Breast test reported at the 39th San Antonio Breast Cancer Symposium demonstrating that the MetaSite Score was significantly associated with increased risk of distant metastasis in Hormone Receptor (HR-positive), HER2-negative Early Stage Breast Cancer (ESBC). Data include results from the Kaiser Permanente Cohort Case-Control Study and the ECOG2197 Clinical Trail Cohort Study led by the ECOG-ACRIN Cancer Research Group. Results from the Kaiser Permanente Cohort Study conducted by MetaStat, demonstrated MetaSite Score was a statically significant predictor of distant metastasis and a binary cut point was able to discriminate high and low risk patient groups when adjusted for clinical factors. Dr. Joseph Sparano, principal investigator for MetaStat’s ECOG2197 Cohort Study, presented data demonstrating the MetaSite Breast™ test is prognostic for distant metastatic recurrence within 5 years and provides complementary prognostic and potentially clinically actionable information to the low/mid-range Recurrence Score from Genomic Health’s Oncotype DX, breast cancer test.